Triomics is a healthcare AI company focused exclusively on oncology workflows. Its platform deploys cancer-specific AI agents that ingest unstructured longitudinal patient records—clinical notes, pathology and molecular reports, biomarker panels, and imaging—and transform them into structured, actionable datasets that flow directly into existing cancer center workflows. Triomics automates labor-intensive tasks such as clinical trial matching, pre-visit charting, and cancer registry curation, with peer-reviewed validation in Nature Digital Medicine showing roughly 67% less manual chart review time, 40% more trial matches, and 30%+ higher enrollment. The platform is used at leading U.S. cancer networks including Memorial Sloan Kettering, MD Anderson, Yale Cancer Center, Mount Sinai, and Texas Oncology, and integrates with EHR systems like Epic. In May 2026 the company raised a $22M Series B led by Battery Ventures to scale adoption and expand its autonomous chart abstraction architecture.